IP Library › Granted Patent US 9,540,618
Granted Patent B2
US 9,540,618 · App. 14/533,857 · Granted Jan 10, 2017

Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses

Inventors: Chien-Hsing Chang (Downingtown, PA); David M. Goldenberg (Mendham, NJ); William J. McBride (Boonton, NJ); Edmund A. Rossi (Woodland Park, NJ)
Assignee: IBC Pharmaceuticals, Inc.
C12N9/12B82Y5/00B82Y10/00C07K16/18C07K16/2803C07K16/2887C07K16/3007C07K16/3092C07K2317/31C07K2317/55C07K2319/00C07K2319/70C12Y207/11011
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,540,618
App. No.
14/533,857
Granted
Jan 10, 2017
Kind
B2
Abstract

The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.

Claims (4)

1. A complex comprising a homodimer, each monomer of the homodimer comprising (i) a dimerization and docking domain (DDD) moiety, wherein the amino acid sequence of the DDD moiety is residues 1 to 44 of human protein kinase A (PKA) regulatory subunit RIIα; attached to (ii) an antigen-binding antibody fragment selected from the group consisting of a F(ab′) 2 , F(ab) 2 , Fab, and scFv.

2. The complex of claim 1 , wherein the monomer is a fusion protein.

3. The complex of claim 1 , wherein the monomer further comprises a linker peptide between the antigen-binding antibody fragment and the DDD.

4. The complex of claim 1 , wherein the antigen-binding antibody fragment is from an antibody selected from the group consisting of a humanized antibody, a human antibody and a chimeric antibody.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2015
From: CHANG, CHIEN-HSING; GOLDENBERG, DAVID M.; MCBRIDE, WILLIAM J.; ROSSI, EDMUND A.
To: IMMUNOMEDICS, INC.
Reel/Frame 035027/0785 →
Continuity (7)
Division 13419614 · Mar 14, 2012
Division 12468589 · May 19, 2009
Division 11389358 · Mar 24, 2006
Provisional Application 60668603 · Apr 6, 2005
Provisional Application 60728292 · Oct 19, 2005
Provisional Application 60751196 · Dec 16, 2005
Related Publication 20150056680A1 · Feb 26, 2015